sur THERACLION (EPA:ALTHE)
Theraclion 2024 Review: Progress and Challenges
Theraclion, a company specializing in non-invasive ultrasound therapy, closes 2024 with significant progress. The pivotal clinical trial for SONOVEIN® met the FDA’s schedule, with treatment completion in June and a 12-month follow-up ongoing. Final results are expected in the summer of 2025, a crucial step to enter the US market.
The SONOVEIN® product continues to show its maturity, with more than 3,000 treatments carried out. In 2024, 29 presentations took place at 25 international events, strengthening the product's reputation.
Theraclion has also chosen to refocus on the varicose veins market. Turnover reached €1,485,000 excluding adjustments, marked by growth in sales of consumables (+9%). In 2025, the company plans to intensify its commercial development.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de THERACLION